# Christine A. Pratilas

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/christine-a-pratilas/

## Facts

| Field | Value |
| --- | --- |
| Citations | 8,734 |
| Field | Neurofibromatosis and Schwannoma Cases |
| h-index | 41 |
| i10-index | 76 |
| Last Known Institution | Johns Hopkins University |
| OpenAlex ID | https://openalex.org/A5075174884 |
| ORCID iD | 0000-0002-7116-0605 |
| Works | 670 |

## Researcher papers

- [BRAF mutation predicts sensitivity to MEK inhibition](https://scholariq.org/papers/braf-mutation-predicts-sensitivity-to-mek-inhibition/)
- [<sup>V600E</sup> BRAF is associated with disabled feedback inhibition of RAF–MEK signaling and elevated transcriptional output of the pathway](https://scholariq.org/papers/sup-v600e-sup-braf-is-associated-with-disabled-feedback-inhibition-of-raf-mek/)
- [Relief of Profound Feedback Inhibition of Mitogenic Signaling by RAF Inhibitors Attenuates Their Activity in BRAFV600E Melanomas](https://scholariq.org/papers/relief-of-profound-feedback-inhibition-of-mitogenic-signaling-by-raf-inhibitors/)
- [The RAF inhibitor PLX4032 inhibits ERK signaling and tumor cell proliferation in a V600E BRAF-selective manner](https://scholariq.org/papers/the-raf-inhibitor-plx4032-inhibits-erk-signaling-and-tumor-cell-proliferation-in/)
- [Loss of NF1 in Cutaneous Melanoma Is Associated with RAS Activation and MEK Dependence](https://scholariq.org/papers/loss-of-nf1-in-cutaneous-melanoma-is-associated-with-ras-activation-and-mek/)
- [Reactivation of ERK Signaling Causes Resistance to EGFR Kinase Inhibitors](https://scholariq.org/papers/reactivation-of-erk-signaling-causes-resistance-to-egfr-kinase-inhibitors/)
- [Genomic and Biological Characterization of Exon 4 KRAS Mutations in Human Cancer](https://scholariq.org/papers/genomic-and-biological-characterization-of-exon-4-kras-mutations-in-human-cancer/)
- [Transcriptional Pathway Signatures Predict MEK Addiction and Response to Selumetinib (AZD6244)](https://scholariq.org/papers/transcriptional-pathway-signatures-predict-mek-addiction-and-response-to/)
- [Genetic Predictors of MEK Dependence in Non–Small Cell Lung Cancer](https://scholariq.org/papers/genetic-predictors-of-mek-dependence-in-non-small-cell-lung-cancer/)
- [Combined EGFR/MEK Inhibition Prevents the Emergence of Resistance in <i>EGFR</i> -Mutant Lung Cancer](https://scholariq.org/papers/combined-egfr-mek-inhibition-prevents-the-emergence-of-resistance-in-i-egfr-i/)
- [Exploring hospital volume thresholds for improved sarcoma treatment across different age categories in the United States](https://scholariq.org/papers/exploring-hospital-volume-thresholds-for-improved-sarcoma-treatment-across/)

## Researcher topics

- [Neurofibromatosis and Schwannoma Cases](https://scholariq.org/topics/neurofibromatosis-and-schwannoma-cases/)
- [Melanoma and MAPK Pathways](https://scholariq.org/topics/melanoma-and-mapk-pathways/)
- [Neuroblastoma Research and Treatments](https://scholariq.org/topics/neuroblastoma-research-and-treatments/)
- [Sarcoma Diagnosis and Treatment](https://scholariq.org/topics/sarcoma-diagnosis-and-treatment/)
- [Advanced Breast Cancer Therapies](https://scholariq.org/topics/advanced-breast-cancer-therapies/)

## Researcher university

- [Johns Hopkins University](https://scholariq.org/institutions/johns-hopkins-university/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.